NASDAQ:MBX MBX Biosciences (MBX) Stock Price, News & Analysis $49.61 -1.10 (-2.17%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$49.74 +0.13 (+0.25%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About MBX Biosciences Stock (NASDAQ:MBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MBX Biosciences alerts:Sign Up Key Stats Today's Range$49.23▼$50.8850-Day Range$48.82▼$68.6252-Week Range$12.94▼$72.64Volume818,908 shsAverage Volume591,618 shsMarket Capitalization$2.39 billionP/E RatioN/ADividend YieldN/APrice Target$87.00Consensus RatingModerate Buy Company Overview MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide therapies for endocrine and metabolic disorders. The company uses its Precision Endocrine Peptide platform to design engineered peptides intended to provide targeted activity, extended duration and more consistent treatment effects. MBX’s lead program, MBX 1416, is an investigational long-acting parathyroid hormone receptor agonist being developed as a potential replacement therapy for people with hypoparathyroidism, a disorder in which the body produces insufficient parathyroid hormone. The company’s broader pipeline is focused on additional peptide-based medicines for endocrine diseases with significant unmet treatment needs. Headquartered in Indianapolis, Indiana, MBX Biosciences is advancing its programs through clinical development and regulatory evaluation. Its therapies are intended for patients in markets where endocrine disorders are treated with approved pharmaceutical products, although specific commercial geographies will depend on future clinical results and regulatory authorizations.AI Generated. May Contain Errors. Read More MBX Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreMBX MarketRank™: 2.636832363825 of 5 starsMBX Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 463rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMBX Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialMBX Biosciences has a consensus price target of $87.00, representing about 75.4% upside from its current price of $49.61.Amount of Analyst CoverageMBX Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MBX Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MBX Biosciences are expected to decrease in the coming year, from ($3.10) to ($4.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MBX Biosciences is -20.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MBX Biosciences is -20.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMBX Biosciences has a P/B Ratio of 6.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.46% of the float of MBX Biosciences has been sold short.Short Interest Ratio / Days to CoverMBX Biosciences has a short interest ratio ("days to cover") of 6.84.Change versus previous monthShort interest in MBX Biosciences has recently increased by 8.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMBX Biosciences does not currently pay a dividend.Dividend GrowthMBX Biosciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.46 News SentimentMBX Biosciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MBX Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MBX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows2 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MBX Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,335.00 in company stock.Percentage Held by Insiders31.09% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsMBX Biosciences has minimal institutional ownership at this time.Read more about MBX Biosciences' insider trading history. Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBX Stock News HeadlinesMBX Biosciences to Participate in Upcoming November Investor ConferencesOctober 13, 2026 | globenewswire.comMBX Biosciences (NASDAQ:MBX) Stock Price Target Raised at Stifel NicolausOctober 12, 2026 | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 18 at 1:00 AM | Awesomely (Ad)MBX Biosciences, Inc. (NASDAQ:MBX) Stock Has Consensus Target Price of $83.89 According to BrokeragesOctober 12, 2026 | americanbankingnews.comIs MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?October 10, 2026 | finance.yahoo.comMBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%October 9, 2026 | finance.yahoo.comMBX Biosciences出席Stifel心臟代謝論壇：管線佈局押注給藥優勢September 30, 2026 | hk.investing.comMBX Biosciences aposta em dosagem diferenciada no pipeline de obesidade e doenças rarasSeptember 30, 2026 | br.investing.comSee More Headlines MBX Stock Analysis - Frequently Asked Questions How have MBX shares performed this year? MBX Biosciences' stock was trading at $31.54 at the beginning of 2026. Since then, MBX stock has increased by 57.3% and is now trading at $49.61. How were MBX Biosciences' earnings last quarter? MBX Biosciences, Inc. (NASDAQ:MBX) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.10. When did MBX Biosciences IPO? MBX Biosciences (MBX) raised $153 million in an IPO on Thursday, September 12th 2024. The company issued 10,200,000 shares at $14.00-$16.00 per share. Who are MBX Biosciences' major shareholders? MBX Biosciences' top institutional shareholders include Koa Wealth Management LLC (0.03%). Insiders that own company stock include Patrick J Heron, Life Sciences X LP Frazier, Edward T Mathers, Carl L Gordon, P Kent Hawryluk, Ora H Pescovitz, Steven L Hoerter and Salomon Azoulay. View institutional ownership trends. How do I buy shares of MBX Biosciences? Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MBX Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Strive (ASST), AST SpaceMobile (ASTS), Celldex Therapeutics (CLDX), Definium Therapeutics (DFTX) and Bloom Energy (BE). Company Calendar Last Earnings8/06/2026Today10/18/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MBX's financial health is in the Green zone, according to TradeSmith. MBX has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MBX Previous SymbolNASDAQ:MBX CIK1776111 Webmbxbio.com Phone(317) 989-3100FaxN/AEmployees63Year Founded2018Price Target and Rating Average Price Target for MBX Biosciences$87.00 High Price Target$150.00 Low Price Target$18.00 Potential Upside/Downside+75.4%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$86.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.02% Return on Assets-24.94% Debt Debt-to-Equity RatioN/A Current Ratio18.08 Quick Ratio18.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book6.04Miscellaneous Outstanding Shares48,160,000Free Float33,187,000Market Cap$2.39 billion OptionableN/A Beta0.10 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MBX) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis link won't stay freeThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
